RxDoctor Payments Data

Wesley Wilson, DO

Family Medicine · Forney, TXNPI 1447256128

Payments from drug & device makers

$4,313in general payments, 2019–2025

Across 217 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$723
  • Otsuka America Pharmaceutical, Inc.$455
  • Novo Nordisk$438
  • AbbVie$341
  • Pfizer$308
  • Johnson & Johnson$201
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,302100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,313 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,200
Medicare patients
81
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$59,262
EliquisApixaban37$34,844
JardianceEmpagliflozin24$27,607
FarxigaDapagliflozin Propanediol19$26,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$21,673
TrulicityDulaglutide11$21,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,892
Soliqua 100-33Insulin Glargine/Lixisenatide11$14,826
Tresiba Flextouch U-200Insulin Degludec15$13,883
JanuviaSitagliptin Phosphate11$10,975
MyrbetriqMirabegron17$8,558
LinzessLinaclotide11$7,513
Gabapentin139$2,021
Albuterol Sulfate HfaAlbuterol Sulfate57$1,832
Atorvastatin Calcium192$1,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$438$59,26238 claims
PfizerEliquis$308$34,84437 claims
Boehringer IngelheimJardiance$147$27,60724 claims
AstraZenecaFarxiga$723$26,30319 claims
Lilly USA, LLCTrulicity$73$21,32611 claims
GSKTrelegy Ellipta$166$18,89225 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$143$14,82611 claims
MerckJanuvia$11$10,97511 claims
Astellas Pharma US IncMyrbetriq$42$8,55817 claims
AbbVieLinzess, Synthroid$341$8,26625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Forney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →